Bristol Orencia Pharmacovigilance Plan Could Become Industry Standard
Executive Summary
Bristol-Myers Squibb's proposed pharmacovigilance program for its rheumatoid arthritis therapy Orencia (abatacept) is indicative of a trend toward enhanced safety monitoring, Arthritis Advisory Committee industry representative Roger Porter (formerly with Wyeth) said Sept. 8
You may also be interested in...
Orencia Marketing Likely To Focus On Broader Mechanism Of Action
Bristol-Myers Squibb is setting the stage to differentiate Orencia from other biologic rheumatoid arthritis therapies with a broader mechanism of action claim
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011